Hepatotoxicity due to antitubercular drugs in multidrug-resistant tuberculosis patients
DOI:
https://doi.org/10.24265/horizmed.2022.v22n1.05Keywords:
Tuberculosis, Multidrug-Resistant, Chemical and Drug Induced Liver Injury, Antitubercular Agents, TuberculosisAbstract
Objective: To describe the clinical characteristics of drug-induced liver injury (DILI) in multidrug-resistant tuberculosis (MDR-TB) patients.
Materials and methods: A retrospective study conducted in hospitalized patients with MDR-TB and DILI. The criteria of the DILI Expert Working Group were used for the diagnosis of DILI, and the RUCAM (Roussel Uclaf Causality Assessment
Method) for the causality analysis. The specific association between DILI and antitubercular drugs was established by drug rechallenge or discontinuation and recovery. Results: Seven cases of MDR-TB and DILI are described in this research. The mean age (standard deviation) was 39.10 (3.30) years.
Mean DILI occurred 30.40 (27.70) days after starting the treatment. Three (43.00 %) patients presented jaundice. Regarding the type of injury, four (57.00 %) had hepatocellular injury and three (43.00 %) cholestatic injury. Four patients showed mild DILI and
three moderate DILI. All the patients had taken pyrazinamide (pyrazinamide alone: four patients; pyrazinamide and ethionamide: one patient; pyrazinamide, rifampin and isoniazid: one patient; pyrazinamide and rifampicin: one patient). The mean hospital stay was 48.10 (48.70) days. The mean serum alkaline phosphatase (AP), alanine aminotransferase (ALT) and gamma-glutamyltranspeptidase (GGT) were 2.40 (1.10), 7.90 (7.10) and 5.60 (3.70) times the upper limit of normal (ULN), respectively. The mean
total bilirubin was 2.30 (2.00), with a range of 0.50 to 6.40 mg/dl. As part of the discharge plan, quinolones were given to seven patients (levofloxacin: six patients; ofloxacin: one patient) and amoxicillin/clavulanic acid was added to one patient. Conclusions: MDR-TB patients may develop DILI after the first month of treatment. Hepatocellular injury was the most
common type of liver injury, and pyrazinamide was the most frequently used antimycobacterial.
Downloads
References
Knight GM, McQuaid CF, Dodd PJ, Houben RMGJ. Global burden of
latent multidrug-resistant tuberculosis: trends and estimates based
on mathematical modelling. Lancet Infect Dis. 2019; 19(8): 903-12.
World Health Organization. Global tuberculosis report 2021
[Internet]. Geneva: World Health Organization; 2021. Disponible en:
https://www.who.int/publications/i/item/9789240037021
Nathanson E, Gupta R, Huamani P, Leimane V, Pasechnikov AD, Tupasi
TE, et al. Adverse events in the treatment of multidrug-resistant
tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung
Dis. 2004; 8(11): 1382-4.
Wu S, Zhang Y, Sun F, Chen M, Zhou L, Wang N, et al. Adverse events
associated with the treatment of multidrug-resistant tuberculosis.
Am J Ther. 2016; 23(2): e521-30.
Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM,
et al. An official ATS statement: hepatotoxicity of antituberculosis
therapy. Am J Respir Crit Care Med. 2006; 174(8): 935-52.
Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H,
et al. Case definition and phenotype standardization in drug-induced
liver injury. Clin Pharmacol Ther. 2011; 89(6): 806-15.
Keshavjee S, Gelmanova IY, Shin SS, Mishustin SP, Andreev YG, Atwood
S, et al. Hepatotoxicity during treatment for multidrug-resistant
tuberculosis: occurrence, management and outcome. Int J Tuberc
Lung Dis. 2012; 16(5): 596-603.
Danan G, Teschke R. RUCAM in drug and herb induced liver injury:
the update. Int J Mol Sci. 2016; 17(1): 14.
Sharma SK, Singla R, Sarda P, Mohan A, Makharia G, Jayaswal A, et
al. Safety of 3 different reintroduction regimens of antituberculosis
drugs after development of antituberculosis treatment–induced
hepatotoxicity. Clin Infect Dis. 2010; 50(6): 833-9.
Lee SS, Lee CM, Kim TH, Kim JJ, Lee JM, Kim HJ, et al. Frequency
and risk factors of drug-induced liver injury during treatment
of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2016;
(6): 800-5.
Törün T, Güngör G, Ozmen I, Bölükbaşi Y, Maden E, Biçakçi B, et
al. Side effects associated with the treatment of multidrug-resistant
tuberculosis. Int J Tuberc Lung Dis. 2005; 9(12): 1373-7.
Gao J-T, Du J, Wu G-H, Pei Y, Gao M-Q, Martinez L, et al.
Bedaquiline-containing regimens in patients with pulmonary
multidrug-resistant tuberculosis in China: focus on the safety.
Infect Dis Poverty. 2021; 10(1): 32.
Molla Y, Wubetu M, Dessie B. Anti-tuberculosis drug induced
hepatotoxicity and associated factors among tuberculosis patients
at selected hospitals, Ethiopia. Hepatic Med. 2021; 13: 1-8.
Trubnikov A, Hovhannesyan A, Akopyan K, Ciobanu A, Sadirova D,
Kalandarova L, et al. Effectiveness and safety of a shorter treatment
regimen in a setting with a high burden of multidrug-resistant
tuberculosis. Int J Environ Res Public Health. 2021; 18(8): 4121.
Shih T-Y, Pai C-Y, Yang P, Chang W-L, Wang N-C, Hu OY-P. A novel
mechanism underlies the hepatotoxicity of pyrazinamide. Antimicrob
Agents Chemother. 2013; 57(4): 1685-90.
Sutherland JJ, Webster YW, Willy JA, Searfoss GH, Goldstein
KM, Irizarry AR, et al. Toxicogenomic module associations with
pathogenesis: a network-based approach to understanding drug
toxicity. Pharmacogenomics J. 2018; 18(3): 377-90.
Chan ED, Laurel V, Strand MJ, Chan JF, Huynh M-LN, Goble M, et al.
Treatment and outcome analysis of 205 patients with multidrug-resistant
tuberculosis. Am J Respir Crit Care Med. 2004; 169(10): 1103-9.
Leimane V, Riekstina V, Holtz TH, Zarovska E, Skripconoka V, Thorpe
LE, et al. Clinical outcome of individualised treatment of multidrug resistant tuberculosis in Latvia: a retrospective cohort study. Lancet.
; 365(9456): 318-26.
Dheda K, Migliori GB. The global rise of extensively drug-resistant
tuberculosis: is the time to bring back sanatoria now overdue?
Lancet. 2012; 379(9817): 773-5.
Evans G. Bad news in the global village: are U.S. hospitals ready for
the XDR-TB strain? World Hosp Health Serv. 2007; 43(3): 46-8.
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Horizonte Médico (Lima)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Horizonte Médico (Lima) (Horiz. Med.) journal’s research outputs are published free of charge and are freely available to download under the open access model, aimed at disseminating works and experiences developed in biomedical and public health areas, both nationally and internationally, and promoting research in the different fields of human medicine. All manuscripts accepted and published in the journal are distributed free of charge under the terms of a Creative Commons license – Attribution 4.0 International (CC BY 4.0).
